Nicholas Saraceno, Editor

The North Carolina project adds 1.4 million square feet of dedicated production space for aseptic manufacturing and finished production processes.

A cross-sectional audit study determines how racial and ethnic disparities—among English, Mandarin, and Spanish-speaking patients—can impact access.

The deal offers member pharmacies two pricing options, which will take effect Aug. 1.

A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.

The agreement will look to further develop cell and gene therapies for the treatment of hematological cancers.

A retrospective study investigates whether use of these portals can be defined by clinical and sociodemographic data.

The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process.

The company acquires Alimera Sciences for $381 million upfront, while establishing its interest in ophthalmology.

A study examines the economical validity of using this therapy as a treatment for unresectable stage III non–small cell lung cancer.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses ways that changes made to reimbursement models are affecting patient therapies in the biosimilar space.

The partnership will offer an end-to-end manufacturing solution for biopharma companies.

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

A cross-sectional study explores the broader issue of whether racial segregation in local acute care hospitals exists, while focusing on the demographic of older Black patients enrolled in Medicare.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses what to expect from Cardinal Health's biosimilars pipeline.

Deal will target neurological diseases, featuring an initial payment of $42 million for Ascidian and up to $1.8 billion in milestone payments/royalties.

The deal also adds a spread of supply chain efficiency, sustainability, and patient safety outcomes to the mix.

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, explains how digital formats help manufacturers better manage price based on real-time data, along with the impact of NDC-specific price dexterity.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health discusses the growing biosimilars market and the challenges associated with regulation and adoption.

A cross-sectional study among patients with both cancer and a SARS-CoV-2 infection investigates if there were racial and ethnic disparities in treatment delays or discontinuations.

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, discusses his first byline with the publication, along with why the industry may be stuck in its ways in certain aspects.

Webinar dives into the trends, technology, and market necessities that can help tackle these obstacles.

The company’s European Hub facility in Roermond is expanding by over 235,000 square feet, and will be dedicated to accommodating freezer farm capacity.

A retrospective cohort study investigates the characteristics of female patients with localized breast cancer that are associated with this nonpersistence.

The 53,000 square-foot facility is expected to become a Northeastern biotech hub, and will be home to various CGT services.

The $530 million investment will accelerate the company’s development and production process for therapies in the rare disease space.

A cohort study explores the connection between the rise in Medicare Advantage plan coverage and enrollee satisfaction.

Beneath all the “organized chaos,” industry shows such as LogiPharma Europe spotlight the valuable opportunity offered by these events to further educate our most valuable asset: our readers.

LogiPharma Europe captured many timely topics, including the importance of next-level approaches in aligning temperature-controlled transit and visibility.